Showing results (271-280 of 369) with videos related to
Sort By:
Pageof 37
The Lancet. Oncology|June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean-Yves Blay, César Serrano, Michael C Heinrich, et al.Cancers|February 15, 2022
Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type FibromatosisAnne-Rose W Schut, Emma Lidington, Milea J M Timbergen, et al.Cancers|June 24, 2022
Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor OutcomesAnne-Rose W Schut, Emma Lidington, Milea J M Timbergen, et al.Journal of Proteomics|April 25, 2021
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometryMartina Milighetti, Lukas Krasny, Alex T J Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.European Journal of Cancer (Oxford, England : 1990)|August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumourSuzanne George, Ping Chi, Michael C Heinrich, et al.JAMA Oncology|March 31, 2022
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical TrialRobin L Jones, Vinod Ravi, Andrew S Brohl, et al.JAMA Oncology|September 10, 2020
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical TrialSeth M Pollack, Mary W Redman, Kelsey K Baker, et al.Molecular Cancer Therapeutics|November 12, 2020
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue SarcomaJavier Martín-Broto, Antonio López Pousa, Andrew S Brohl, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudySebastian Bauer, Michael C Heinrich, Suzanne George, et al.Pageof 37